Share on StockTwits

Boston Scientific (NYSE:BSX) EVP Michael P. Phalen sold 13,500 shares of the stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $13.02, for a total value of $175,770.00. Following the transaction, the executive vice president now directly owns 127,486 shares of the company’s stock, valued at approximately $1,659,868. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Boston Scientific (NYSE:BSX) traded down 2.48% on Tuesday, hitting $12.60. The stock had a trading volume of 37,104,584 shares. Boston Scientific has a 52-week low of $8.95 and a 52-week high of $14.08. The stock has a 50-day moving average of $12.87 and a 200-day moving average of $12.86. The company has a market cap of $16.666 billion and a P/E ratio of 47.33. Boston Scientific also was the target of a significant decrease in short interest during the month of May. As of May 30th, there was short interest totalling 20,214,310 shares, a decrease of 11.0% from the May 15th total of 22,700,471 shares. Based on an average daily volume of 10,811,012 shares, the days-to-cover ratio is presently 1.9 days. Currently, 1.5% of the shares of the company are sold short.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Tuesday, April 29th. The company reported $0.16 earnings per share for the quarter, missing the analysts’ consensus estimate of $0.18 by $0.02. The company had revenue of $1.77 billion for the quarter, compared to the consensus estimate of $1.80 billion. During the same quarter last year, the company posted $0.16 earnings per share. Boston Scientific’s revenue was up .7% compared to the same quarter last year. Analysts expect that Boston Scientific will post $0.80 EPS for the current fiscal year.

A number of research firms have recently commented on BSX. Analysts at Morgan Stanley initiated coverage on shares of Boston Scientific in a research note on Tuesday, June 10th. They set an “overweight” rating and a $15.00 price target on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Boston Scientific in a research note on Friday, May 30th. They now have a $14.00 price target on the stock. Finally, analysts at TheStreet upgraded shares of Boston Scientific from a “hold” rating to a “buy” rating in a research note on Thursday, May 1st. Six equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $14.05.

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.